Noom Partners with LillyDirect Pharmacy Provider to Expand Access to Weight Loss Drug Zepbound
**Noom Partners with LillyDirect Pharmacy Provider to Expand Access to Weight Loss Drug Zepbound**
*April 2024 – In a strategic move to broaden access to weight management solutions, digital health company Noom has announced a partnership with LillyDirect, the direct-to-consumer pharmacy service from pharmaceutical giant Eli Lilly. The collaboration aims to streamline access to Zepbound, Eli Lilly’s recently approved weight loss drug, for eligible Noom users.*
### A New Chapter in Digital Health and Weight Management
Noom, widely known for its psychology-based weight loss app, has been expanding its offerings into the clinical weight loss space. The company launched Noom Med in 2023, a telehealth platform that connects users with clinicians for personalized weight loss plans, including the potential prescription of anti-obesity medications.
The partnership with LillyDirect marks a significant step in Noom’s evolution from a behavioral health app to a comprehensive weight management platform. Through this collaboration, Noom Med users who are prescribed Zepbound will now have the option to fill their prescriptions directly through LillyDirect’s online pharmacy services, simplifying the process and improving medication adherence.
### What is Zepbound?
Zepbound (tirzepatide) is a once-weekly injectable medication developed by Eli Lilly. It was approved by the U.S. Food and Drug Administration (FDA) in late 2023 for chronic weight management in adults with obesity or overweight conditions and at least one weight-related health issue, such as hypertension or type 2 diabetes.
Zepbound works by mimicking two gut hormones—GLP-1 and GIP—that regulate appetite and insulin secretion. Clinical trials have shown that patients taking Zepbound can lose up to 20% of their body weight when combined with diet and exercise, making it one of the most effective weight loss drugs currently available.
### How the Partnership Works
Under the new partnership:
– **Noom Med users** who meet the clinical criteria for Zepbound and receive a prescription from a Noom-affiliated healthcare provider will be offered the option to have their medication fulfilled through LillyDirect.
– **LillyDirect** will handle the prescription processing, insurance coordination, and home delivery of Zepbound, offering a seamless experience for patients.
– **Integrated support** will be provided through Noom’s digital platform, including behavioral coaching, nutrition guidance, and progress tracking, to complement the pharmacological treatment.
This integrated approach is designed to address both the physiological and psychological aspects of weight loss, which experts say is key to long-term success.
### Expanding Access and Reducing Barriers
One of the primary goals of the partnership is to reduce barriers to accessing effective weight loss treatments. Despite the growing availability of anti-obesity medications, many patients face challenges such as high out-of-pocket costs, insurance hurdles, and logistical difficulties in obtaining prescriptions.
By leveraging LillyDirect’s pharmacy infrastructure and Noom’s digital health ecosystem, the partnership aims to:
– **Improve medication accessibility** for eligible users across the United States.
– **Enhance patient convenience** through home delivery and virtual care.
– **Support long-term adherence** by integrating medication with behavioral and lifestyle interventions.
### Industry Implications
The Noom-LillyDirect collaboration reflects a broader trend in healthcare toward integrated, patient-centered solutions that combine digital tools with pharmaceutical innovation. As more weight loss drugs enter the market and demand for obesity treatment grows, partnerships like this are likely to become increasingly common.
“This partnership is a significant milestone in our mission to make effective weight management more accessible,” said Geoff Cook, CEO of Noom. “By combining Noom’s behavioral science with Lilly’s pharmaceutical expertise, we’re creating a powerful ecosystem that supports users every step of the way.”
### Looking Ahead
As the obesity epidemic continues to affect millions of Americans, the need for scalable, effective, and accessible treatment options has never been greater. The Noom and LillyDirect partnership represents a promising model for how digital health platforms and pharmaceutical companies can work together to meet this challenge.
With Zepbound now more easily accessible to Noom users, the collaboration could pave the way for similar initiatives that blend medication, technology, and behavioral support to tackle one of the most pressing public health issues of our time.
—
*Disclaimer: Zepbound is a prescription medication and is not suitable for everyone. Patients should consult with a qualified healthcare provider to determine if it is appropriate for their individual needs.*
Read More